| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5496931 | PARAPRO LLC | Insecticide and miticide A83543 compounds and their method of production by fermentation |
Mar, 2013
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6342482 | PARAPRO LLC | Formulations for controlling human lice |
Jun, 2019
(4 years ago) | |
| US7030095 | PARAPRO LLC | Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs |
Jul, 2021
(2 years ago) | |
| US6063771 | PARAPRO LLC | Formulations for controlling human lice |
Jul, 2023
(9 months ago) | |
| US9895388 | PARAPRO LLC | Methods and compositions useful for controlling cutaneous mites |
Nov, 2033
(9 years from now) | |
Natroba is owned by Parapro Llc.
Natroba contains Spinosad.
Natroba has a total of 5 drug patents out of which 4 drug patents have expired.
Expired drug patents of Natroba are:
- US6342482
- US7030095
- US6063771
- US5496931
Natroba was authorised for market use on 18 January, 2011.
Natroba is available in suspension;topical dosage forms.
Natroba can be used as the product composition (natroba) is for the topical treatment of human scabies mite infestations by melting and delivering the active ingredient, spinosad, to the stratum corneum where scabies mites live and breed, natroba topical suspension is a pediculicide indicated for the topical treatment of head lice infestation in patients six (6) months of age and older., topical treatment of head lice infestation in patients four (4) years of age and older.
Drug patent challenges can be filed against Natroba from 18 January, 2015.
The generics of Natroba are possible to be released after 25 November, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-858) | Apr 28, 2024 |
| M(M-152) | Nov 30, 2017 |
| New Chemical Entity Exclusivity(NCE) | Jan 18, 2016 |
Drugs and Companies using SPINOSAD ingredient
NCE-1 date: 18 January, 2015
Market Authorisation Date: 18 January, 2011
Treatment: Topical treatment of head lice infestation in patients four (4) years of age and older; Natroba topical suspension is a pediculicide indicated for the topical treatment of head lice infestation in pat...
Dosage: SUSPENSION;TOPICAL
NATROBA family patents
